Associated Papers
Evaluation of KRAS and NRAS mutations in metastatic colorectal cancer: an 8-year study of 10 754 patients in Turkey.
Kavgaci G et al.
Molecular Oncology, 2025
A structurally informed human protein-protein interactome reveals proteome-wide perturbations caused by disease mutations.
Xiong D et al.
Nature Biotechnology, 2025
Potential genetic biomarker of Saudi Arabian patients with colorectal cancer.
Younis NS et al.
European Review for Medical and Pharmacological Sciences, 2022
Enhanced interpretation of 935 hotspot and non-hotspot RAS variants using evidence-based structural bioinformatics.
Tripathi S et al.
Computational and Structural Biotechnology Journal, 2022
34976316 (PubMed )
Supplement: mmc1.docx
Binimetinib, a novel MEK1/2 inhibitor, exerts anti-leukemic effects under inactive status of PI3Kinase/Akt pathway.
Sakakibara K et al.
International Journal of Hematology, 2019
Peripheral lung adenocarcinomas with KRAS mutations are more likely to invade visceral pleura.
Raparia K et al.
Archives of Pathology & Laboratory Medicine, 2015
[KRAS gene mutation in colorectal cancer].
Roa I et al.
Revista Medica De Chile, 2013
A vertically stacked, polymer, microfluidic point mutation analyzer: rapid high accuracy detection of low-abundance K-ras mutations.
Han K et al.
Analytical Biochemistry, 2011
Fluoride complexes of oncogenic Ras mutants to study the Ras-RasGap interaction.
Gremer L et al.
Biological Chemistry, 2008
The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders.
Aoki Y et al.
Human Mutation, 2008
Augmentation of immune response by an analog of the antigenic peptide in a human T-cell clone recognizing mutated Ras-derived peptides.
Yokomizo H et al.
Human Immunology, 1997
Select a paper to view details